Active Ingredient(s):Pralatrexate FDA Approved: * September 24, 2009 Pharm Company: *ALLOS THERAPEUTICS, INC Category:Cancer
Pralatrexate, sold under the brand name Folotyn, is a medication used for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL).
Pralatrexate was approved for medical use in the United States in September 2009, as the first treatment for Peripheral T-cell Lymphoma (PTCL), an often aggressive type of non-Hodgkins lymphoma.
1 Medical uses
4 Society and culture
* May have multiple approval dates, manufacturers, or labelers. 1 Discussion